EA201890818A1 - Режим комбинированной терапии для лечения hcv - Google Patents

Режим комбинированной терапии для лечения hcv

Info

Publication number
EA201890818A1
EA201890818A1 EA201890818A EA201890818A EA201890818A1 EA 201890818 A1 EA201890818 A1 EA 201890818A1 EA 201890818 A EA201890818 A EA 201890818A EA 201890818 A EA201890818 A EA 201890818A EA 201890818 A1 EA201890818 A1 EA 201890818A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
hcv
combined
compound
combined treatment
Prior art date
Application number
EA201890818A
Other languages
English (en)
Inventor
Мария Глория Бёмон
Лив Бийненс
Лоуренс М. Блатт
Сушмита Мукхержее Чанда
Джон Фрай
Юджин Йанс
Томас Наоки Какуда
Сиви Махадеван
Роел Мертенс
Гастон Рафаэль Пичио
Алекс Ван Дийк
Питер Ван Ремоортер
Дэвид Апелиан
Давей Чэнь
Милинд Дешпанде
Джеймс Хуэй
Авинаш Фадке
Original Assignee
Янссен Фармасьютикалс, Инк.
Ачиллион Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармасьютикалс, Инк., Ачиллион Фармасьютикалс, Инк. filed Critical Янссен Фармасьютикалс, Инк.
Publication of EA201890818A1 publication Critical patent/EA201890818A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Композиция, представляющая собой композицию с фиксированными дозами, содержащую соединение (I), соединение (II) и соединение (III), для лечения гепатита C, и способы ее изготовления.
EA201890818A 2015-09-29 2016-09-29 Режим комбинированной терапии для лечения hcv EA201890818A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562234408P 2015-09-29 2015-09-29
US201662299338P 2016-02-24 2016-02-24
US201662353708P 2016-06-23 2016-06-23
US201662365541P 2016-07-22 2016-07-22
PCT/US2016/054561 WO2017059147A1 (en) 2015-09-29 2016-09-29 Combination therapy regimen for treatment of hcv

Publications (1)

Publication Number Publication Date
EA201890818A1 true EA201890818A1 (ru) 2018-09-28

Family

ID=58406227

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890818A EA201890818A1 (ru) 2015-09-29 2016-09-29 Режим комбинированной терапии для лечения hcv

Country Status (11)

Country Link
US (2) US20170087174A1 (ru)
EP (1) EP3355991A1 (ru)
JP (1) JP2018529777A (ru)
KR (1) KR20180071276A (ru)
AU (1) AU2016331073A1 (ru)
BR (1) BR112018006206A2 (ru)
CA (1) CA3000415A1 (ru)
EA (1) EA201890818A1 (ru)
IL (1) IL258228A (ru)
MA (1) MA43051A (ru)
WO (1) WO2017059147A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
US12031128B2 (en) 2021-04-07 2024-07-09 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908313A1 (en) * 2013-04-05 2014-10-09 Alios Biopharma, Inc. Hepatitis c viral infection treatment using a combination of compounds
JP2016522172A (ja) * 2013-04-12 2016-07-28 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖを治療するのに有用な重水素化されたヌクレオシドプロドラッグ
CA2912682C (en) * 2013-05-16 2021-07-06 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives
US9738629B2 (en) * 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
MA40844A (fr) * 2014-11-10 2017-09-20 Glaxosmithkline Ip No 2 Ltd Compositions pharmaceutiques à action prolongée pour l'hépatite c
SG11201703646SA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Combination long acting compositions and methods for hepatitis c
US20180021361A1 (en) * 2016-07-22 2018-01-25 Janssen Pharmaceuticals, Inc. Combination drug treatment for hepatitis c infection

Also Published As

Publication number Publication date
US20170319572A1 (en) 2017-11-09
US20170087174A1 (en) 2017-03-30
IL258228A (en) 2018-05-31
CA3000415A1 (en) 2017-04-06
KR20180071276A (ko) 2018-06-27
JP2018529777A (ja) 2018-10-11
EP3355991A1 (en) 2018-08-08
WO2017059147A1 (en) 2017-04-06
AU2016331073A1 (en) 2018-05-10
MA43051A (fr) 2018-08-08
BR112018006206A2 (pt) 2018-10-09

Similar Documents

Publication Publication Date Title
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201790630A1 (ru) Способы получения рибозидов
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EA201890731A1 (ru) Модуляторы корового белка гепатита b
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201791046A8 (ru) Макроциклические пептиды, используемые в качестве иммуномодуляторов
MX2018006148A (es) Inhibidores de cxcr2.
DK3245206T3 (da) Pyrazinforbindelser til behandling af infektionssygdomme
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201691991A1 (ru) Мультиспецифические антитела
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201890572A1 (ru) Биофармацевтические композиции
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201792287A1 (ru) Способы лечения рака
EA201692034A1 (ru) Новые макроциклические соединения
EA201891586A1 (ru) Антипролиферативные соединения и их фармацевтические композиции и применения
EA201791174A1 (ru) Антимикотическое соединение
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
EA201690594A1 (ru) Состав для лечения вич-инфекции на основе атазанавира и кобицистата